Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.40 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320227 | 0.89 | ALDH1A1 (0.46) | XPNPEP2ACEMAPTALDH1A1LMNA | |
| SCHEMBL20340601 | 0.88 | LMNA (0.42) | NOTUMXPNPEP2ACEMAPTALDH1A1 | |
| SCHEMBL7882719 | 0.84 | MAPT (0.44) | NOTUMMAPTALDH1A1LMNAHRH3 | |
| SCHEMBL12259250 | 0.84 | MAPT (0.44) | NOTUMMAPTALDH1A1LMNAHRH3 | |
| SCHEMBL12258806 | 0.84 | MAPT (0.44) | NOTUMMAPTALDH1A1LMNAHRH3 | |
| SCHEMBL20970520 | 0.79 | KMT2A (0.51) | MAPTLMNAPOLB | |
| SCHEMBL1874567 | 0.75 | HRH3 (0.45) | MAPTALDH1A1LMNAHRH3 | |
| SCHEMBL19617146 | 0.75 | MEN1 (0.37) | NOTUMMAPTALDH1A1 | |
| SCHEMBL12614195 | 0.75 | NOTUM (0.37) | NOTUMMAPTALDH1A1LMNAPOLB | |
| SCHEMBL23252304 | 0.74 | MEN1 (0.32) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | NOTUM 4409/4885XPNPEP2 2110/4885ACE 2805/4885 |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | NOTUM 4266/4885XPNPEP2 2392/4885ACE 3366/4885 |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | NOTUM 4409/4885XPNPEP2 2110/4885ACE 2805/4885 |
| US-20230044941-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | NOTUM 4282/4885XPNPEP2 2433/4885ACE 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.